IL DONG PHARMACEUTICAL CO., LTD.
Financials
Valuation Metrics
IL DONG PHARMACEUTICAL CO., LTD.'s Market Cap is ₩4809B. At end of 2025 it was ₩1.2T. Ranked #487 of 2,433 in KR market (top 20%), #306 of 786 on KOSPI (top 39%), #56 of 233 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-08-14)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 480.90B KRW | KR#487/2,433 Sec#56/233 |
| Revenue | 572.95B KRW | KR#569/2,433 Sec#26/233 |
| Net Income | 30.57B KRW | KR#529/2,433 Sec#35/233 |
| Total Assets | 573.03B KRW | KR#690/2,433 Sec#39/233 |
| Net Assets | 239.51B KRW | KR#832/2,433 Sec#53/233 |
| Employees | 1,056 | KR#243/2,433 Sec#16/233 |
| Value | ||
| P/E | 15.73x | KR#1,022/2,433 Sec#59/233 |
| P/B | 2.01x | KR#1,933/2,433 Sec#145/233 |
| PEG | 0.01x | KR#95/2,433 Sec#4/233 |
| P/S | 0.84x | KR#1,250/2,433 Sec#65/233 |
| EV/EBITDA | 22.06x | KR#1,076/2,433 Sec#61/233 |
| FCF Yield | 1.10% | KR#1,127/2,433 Sec#80/233 |
| Profitability | ||
| ROE | 12.77% | KR#386/2,433 Sec#26/233 |
| ROA | 5.34% | KR#653/2,433 Sec#49/233 |
| Op. Margin | 4.28% | KR#1,042/2,433 Sec#78/233 |
| Revenue Growth | 4.43% | KR#1,304/2,433 Sec#122/233 |
| Earnings Growth | 1376.63% | KR#55/2,433 Sec#6/233 |
| Financial Health | ||
| Debt Ratio | 139.25% | KR#1,863/2,433 Sec#207/233 |
| Total Debt | 124.63B KRW | KR#613/2,433 Sec#33/233 |
| FCF | 5.30B KRW | KR#887/2,433 Sec#62/233 |
| Cash | 64.85B KRW | KR#625/2,433 Sec#34/233 |
| Current Ratio | 0.99x | KR#1,610/2,433 Sec#171/233 |
| Net Debt/EBITDA | 2.44x | KR#880/2,433 Sec#62/233 |
| Dividend | ||
| Div. Yield | 1.32% | KR#1,027/2,433 Sec#58/233 |
| Performance | ||
| 1Y Return | -27.79% | KR#1,593/2,433 Sec#139/233 |
| 1M Return | 5.63% | KR#1,162/2,433 Sec#116/233 |
| From 52W High | -66.26% | KR#2,128/2,433 Sec#188/233 |
| 1Y MDD | -72.57% | KR#2,054/2,433 Sec#182/233 |
| Trading | ||
| Volume | 77,443 shares | KR#1,140/2,433 Sec#99/233 |
| Trading Value | 1.18B KRW | KR#781/2,433 Sec#69/233 |
| Foreign Own. | 10.83% | KR#431/2,433 Sec#37/233 |
| Per Share | ||
| EPS | 966 KRW | KR#695/2,433 Sec#46/233 |
| BPS | 7,570 KRW | KR#1,136/2,433 Sec#82/233 |
Company Info
Established in 2016, this company manufactures and sells pharmaceuticals, raw materials, and health supplements. Its main products include the active vitamin AROAMIN series and the antibiotic FULUMARIN, which are sold domestically and internationally through various channels. The company conducts R&D for metabolic and respiratory disease treatments, with its COVID-19 treatment ID32124 (Xocova) having received approval in Japan, advancing its global new drug development and commercialization. Ildong Pharmaceutical was founded in 2016 and is headquartered in Seocho-gu, Seoul.